Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Hagberg

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
Pageof 5